NIR‐Assisted MgO‐Based Polydopamine Nanoparticles for Targeted Treatment of Parkinson's Disease through the Blood–Brain Barrier (Adv. Healthcare Mater. 23/2022)

Parkinson's Disease In article 2201655, Yan-Qing Guan and co-workers successfully develop a novel photo-controlled drug delivery system for the treatment of Parkinson's disease. This nanoparticle uses MgO nanoparticles as a substrate, polydopamine as a shell and carries anti-SNCA plasmid and puerarin. Under the irradiation of 808 nm near-infrared light, the composite nanoparticles in deep tissues are activated, then absorbed by nerve cells after penetrating the blood–brain barrier, playing the role of antioxidation, anti-inflammation and inhibiting the accumulation of α-synuclein. Therefore, this strategy for intracerebral drug delivery can be an ideal approach to combat neurodegenerative diseases.